Anidulafungin

Antifungal

Also known as: Eraxis, Anidulafungin Injectable, LY303366

EchinocandinsResearch phase: FDA-approvedRegulatory: FDA-approved (2006) for invasive candidiasis and esophageal candidiasis (Eraxis).

Mechanism

Anidulafungin is the third FDA-approved echinocandin antifungal, sharing the same cell wall-targeting mechanism as caspofungin and micafungin. Its unique feature is that it is eliminated by slow chemical degradation in the blood rather than liver metabolism, meaning it has virtually no drug interactions and requires no dose adjustment for liver or kidney disease.

Technical detail

Anidulafungin is a semisynthetic echinocandin lipopeptide derived from echinocandin B (Aspergillus nidulans). It inhibits 1,3-beta-D-glucan synthase (FKS1 subunit) identically to other echinocandins. Uniquely, anidulafungin undergoes slow non-enzymatic chemical degradation (ring opening at physiological pH and temperature) rather than hepatic metabolism, resulting in no significant CYP450 interactions. Half-life is approximately 26-40 hours. Fungicidal against Candida, fungistatic against Aspergillus.

Build a personalized protocol with Anidulafungin →